Evidence map›Paper›PMID 42237848›Full record

ArticlemAbs2026

Generation of human sequence antibodies in OmniChicken against the highly conserved mammalian target BDNF using three distinct discovery workflows.

Kathryn H Ching, Sinéad Keating, Baisen Zeng, Diego A Espinosa, Edwina Stack, Siobhan Wall, Sonia Beyer, Jason Wade, Amy Tam, Orla Cunningham and 7 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in mAbs, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Kathryn H ChingOmniAb, Inc., Emeryville, California, USA.
Sinéad KeatingBiomedicine Design, Pfizer Inc., Dublin, IE.
Baisen ZengOmniAb, Inc., Emeryville, California, USA.ORCID 0000-0002-7780-3501
Diego A EspinosaOmniAb, Inc., Emeryville, California, USA.
Edwina StackBiomedicine Design, Pfizer Inc., Dublin, IE.
Siobhan WallBiomedicine Design, Pfizer Inc., Dublin, IE.
Sonia BeyerBiomedicine Design, Pfizer Inc., Dublin, IE.
Jason WadeBiomedicine Design, Pfizer Inc., Cambridge, MA, USA.
Amy TamBiomedicine Design, Pfizer Inc., Cambridge, MA, USA.
Orla CunninghamBiomedicine Design, Pfizer Inc., Dublin, IE.
Robayet ChowdhuryOmniAb, Inc., Emeryville, California, USA.
Yulei ZhangOmniAb, Inc., Emeryville, California, USA.
Jacqueline MoralesOmniAb, Inc., Emeryville, California, USA.
Yasmina AbdicheOmniAb, Inc., Emeryville, California, USA.ORCID 0009-0001-8611-2438
Philip A LeightonOmniAb, Inc., Emeryville, California, USA.
Alfredo Darmanin SheehanBiomedicine Design, Pfizer Inc., Dublin, IE.
William HarrimanOmniAb, Inc., Emeryville, California, USA.ORCID 0009-0009-5015-8256

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Generation of antibodies against highly conserved mammalian targets remains a substantial challenge in the therapeutic antibody space. Naïve and synthetic libraries address this need through rounds of

Indexed as

Brain-Derived Neurotrophic FactorImmunoglobulin Heavy ChainsImmunoglobulin Light ChainsAnimalsAnimals, Genetically ModifiedAntibody AffinityCell Surface Display TechniquesChickensHumansMiceBrain-Derived Neurotrophic FactorImmunoglobulin Heavy ChainsImmunoglobulin Light ChainsAntibody discoveryphage displaysingle B cellSPRtransgenic animal

Identifiers

PMID42237848
PMCPMC13240955

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.